Literature DB >> 4062453

Combined hepatic and renal injury in alcoholics during therapeutic use of acetaminophen.

G A Kaysen, S M Pond, M H Roper, D J Menke, M A Marrama.   

Abstract

Combined hepatocellular injury and renal tubular necrosis developed in five alcoholic patients who were receiving acetaminophen therapeutically. Two patients were taking doses prescribed by a physician. The hepatitis was characterized by extremely high serum transaminase values that were maximal on admission. Two patients died, and autopsy disclosed hepatic centrizonal necrosis and acute renal tubular necrosis. The three who survived had clinical features typical of acute tubular necrosis. All five had measurable concentrations of acetaminophen in plasma, although measurements were requested on admission only in two patients. When an alcoholic presents with combined hepatic and renal insufficiency, acetaminophen should be considered as a possible inciting agent. This diagnosis should be considered when serum transaminase levels are markedly elevated and when renal failure is due to acute tubular necrosis.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 4062453

Source DB:  PubMed          Journal:  Arch Intern Med        ISSN: 0003-9926


  5 in total

Review 1.  Just the berries: Nephrotoxic drugs.

Authors:  Tom Hewlett
Journal:  Can Fam Physician       Date:  2004-05       Impact factor: 3.275

Review 2.  Effects of non-narcotic analgesics on the liver.

Authors:  L F Prescott
Journal:  Drugs       Date:  1986       Impact factor: 9.546

3.  Liver disease in the alcoholic.

Authors:  A Szilagyi
Journal:  Can Fam Physician       Date:  1986-09       Impact factor: 3.275

Review 4.  Paracetamol, alcohol and the liver.

Authors:  L F Prescott
Journal:  Br J Clin Pharmacol       Date:  2000-04       Impact factor: 4.335

5.  A novel approach for estimating ingested dose associated with paracetamol overdose.

Authors:  Todd J Zurlinden; Kennon Heard; Brad Reisfeld
Journal:  Br J Clin Pharmacol       Date:  2015-12-09       Impact factor: 4.335

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.